Curis share price today

(CRIS)

Curis share price is $3.08 & ₹261.73 as on 21 Dec 2024, 2.30 'hrs' IST

$3.08

▲

0.01

(0.33%)

Market is closed - opens 8 PM, 23 Dec 2024

View live Curis share price in Dollar and Rupees. Guide to invest in Curis from India. Also see the sentimental analysis on Indian investors investing in Curis. Get details on the Indian mutual funds that are investing in Curis. Get Analyst recommendations and forecasts along with all the Curis's financials.

Curis share price movements

Today's Low: $3.05
Today's High: $3.26
$3.08
0.97%
Downside
Day's Volatility :6.44%
Upside
5.52%
52 Weeks Low: $3.05
52 Weeks High: $17.49
$3.08
0.97%
Downside
52 Weeks Volatility :82.56%
Upside
82.39%

Curis Returns

Period	Curis Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-45.39%	-11.1%	0.0%
6 Months	-62.44%	-6.0%	0.0%
1 Year	-77.65%	2.7%	0.0%
3 Years	-96.93%	0.6%	-19.7%

Curis Key Statistics

in dollars & INR

Previous Close	$3.07
Open	$3.05
Today's High	$3.26
Today's Low	$3.05
Market Capitalization	$26.1M
Today's Volume	$118.0K
52 Week High	$17.49
52 Week Low	$3.05
Revenue TTM	$10.2M
EBITDA	$-49.3M
Earnings Per Share (EPS)	$-7.77
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-372.68%

How to invest in Curis from India?

It is very easy for Indian residents to invest directly in Curis from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Curis stock in both Indian Rupees (INR) and US Dollars (USD). Search for Curis or CRIS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Curis or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Curis shares which would translate to 0.276 fractional shares of Curis as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Curis, in just a few clicks!

Returns in Curis for Indian investors in Rupees

Investment Value

₹1,00,000

Curis investment value today

Current value as on today

₹1,79,845

Returns

₹79,845

(+79.84%)

Returns from Curis Stock

₹77,649 (false-77.65%)

Dollar Returns

₹2,196 (+2.2%)

Indian investors sentiment towards Curis

-44%

Period: Sep 21, 2024 to Dec 20, 2024. Change in 30 Days versus previous period

Search volume for Curis on INDmoney from India has reduced in the last 30 days as on Dec 21, 2024. -44% less investors are searching Curis in the last 30 days versus the previous period.

Global Institutional Holdings in Curis

Maverick Capital Ltd
6.88%
M28 Capital Management LP
4.98%
Vanguard Group Inc
3.24%
CM Management, LLC
1.42%
Renaissance Technologies Corp
1.11%
Citigroup Inc
1.09%

Analyst Recommendation on Curis

Buy

83%Buy

16%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Curis(by analysts ranked 0 to 5 stars)

Based on 12 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Curis

What analysts predicted

Upside of 581.82%

Current:

$3.08

Target:

$21.00

Insights on Curis

Price Movement
In the last 7 days, CRIS stock has moved down by -13.7%
Increasing Revenue
Revenue is up for the last 3 quarters, 2.08M → 2.93M (in $), with an average increase of 15.6% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -11.87M → -10.09M (in $), with an average increase of 8.8% per quarter
CRIS vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 35.5% return, outperforming this stock by 111.2%
CRIS vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 23.0% return, outperforming this stock by 119.8%
Price to Sales
ForCRIS every $1 of sales, investors are willing to pay $1.8, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.9 for every $1 of sales.

Curis Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$10.4M	↑ 5.35%
Net Income	$-32.6M	↓ 38.9%
Net Profit Margin	-312.38%	↑ 226.28%

	FY19	Y/Y Change
Revenue	$10.0M	↓ 4.07%
Net Income	$-36.8M	↑ 12.98%
Net Profit Margin	-367.89%	↓ 55.51%

	FY20	Y/Y Change
Revenue	$10.8M	↑ 8.31%
Net Income	$-34.9M	↓ 5.22%
Net Profit Margin	-321.93%	↑ 45.96%

	FY21	Y/Y Change
Revenue	$10.6M	↓ 1.72%
Net Income	$-50.6M	↑ 45.18%
Net Profit Margin	-475.54%	↓ 153.61%

	FY22	Y/Y Change
Revenue	$10.2M	↓ 4.57%
Net Income	$-60.3M	↑ 19.12%
Net Profit Margin	-593.62%	↓ 118.08%

	FY23	Y/Y Change
Revenue	$10.0M	↓ 1.37%
Net Income	$-47.4M	↓ 21.4%
Net Profit Margin	-473.04%	↑ 120.58%

	Q2 FY23	Q/Q Change
Revenue	$2.2M	↓ 4.35%
Net Income	$-12.0M	↑ 4.09%
Net Profit Margin	-544.42%	↓ 44.16%

	Q3 FY23	Q/Q Change
Revenue	$2.8M	↑ 28.95%
Net Income	$-12.2M	↑ 1.84%
Net Profit Margin	-429.97%	↑ 114.45%

	Q4 FY23	Q/Q Change
Revenue	$2.7M	↓ 4.84%
Net Income	$-11.8M	↓ 3.29%
Net Profit Margin	-436.94%	↓ 6.97%

	Q1 FY24	Q/Q Change
Revenue	$2.1M	↓ 22.63%
Net Income	$-11.9M	↑ 0.81%
Net Profit Margin	-569.32%	↓ 132.38%

	Q2 FY24	Q/Q Change
Revenue	$2.5M	↑ 22.05%
Net Income	$-11.8M	↓ 0.61%
Net Profit Margin	-463.59%	↑ 105.73%

	Q3 FY24	Q/Q Change
Revenue	$2.9M	↑ 15.12%
Net Income	$-10.1M	↓ 14.5%
Net Profit Margin	-344.32%	↑ 119.27%

	FY18	Y/Y Change
Profit	$9.9M	↑ 4.92%

	FY19	Y/Y Change
Profit	$9.5M	↓ 3.69%

	FY20	Y/Y Change
Profit	$10.3M	↑ 8.42%

	FY21	Y/Y Change
Profit	$10.1M	↓ 1.8%

	FY22	Y/Y Change
Profit	$9.9M	↓ 2.09%

	FY23	Y/Y Change
Profit	$10.0M	↑ 1.19%

	Q2 FY23	Q/Q Change
Profit	$2.1M	↓ 6.6%

	Q3 FY23	Q/Q Change
Profit	$2.8M	↑ 30.62%

	Q4 FY23	Q/Q Change
Profit	$2.5M	↓ 8.47%

	Q1 FY24	Q/Q Change
Profit	$1.6M	↓ 36.13%

	Q2 FY24	Q/Q Change
Profit	$2.5M	↑ 56.32%

	Q3 FY24	Q/Q Change
Profit	$2.9M	↑ 14.8%

	FY18	Y/Y Change
Operating Cash Flow	$-30.1M	↓ 37.82%
Investing Cash Flow	$21.4M	↓ 688.82%
Financing Cash Flow	$-6.0M	↓ 109.28%

	FY19	Y/Y Change
Operating Cash Flow	$-26.2M	↓ 12.84%
Investing Cash Flow	$-4.5M	↓ 120.85%
Financing Cash Flow	$23.3M	↓ 490.39%

	FY20	Y/Y Change
Operating Cash Flow	$-25.7M	↓ 1.78%
Investing Cash Flow	$-49.0M	↑ 1000.72%
Financing Cash Flow	$188.8M	↑ 711.37%

	FY21	Y/Y Change
Operating Cash Flow	$-37.6M	↑ 46.16%
Investing Cash Flow	$-47.9M	↓ 2.35%
Financing Cash Flow	$-4.2M	↓ 102.21%

	FY22	Y/Y Change
Operating Cash Flow	$-54.3M	↑ 44.44%
Investing Cash Flow	$33.0M	↓ 168.95%
Financing Cash Flow	$867.0K	↓ 120.78%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-7.9M	↓ 35.5%
Investing Cash Flow	$-3.2M	↓ 112.02%
Financing Cash Flow	$-852.0K	↓ 57.53%

Curis Technicals Summary

Sell

Neutral

Buy

Curis is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Curis Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Curis Inc	-24.88%	-62.44%	-77.65%	-96.93%	-90.13%
Regeneron Pharmaceuticals, Inc.	-5.73%	-34.03%	-17.11%	13.66%	87.56%
Biontech Se	4.48%	30.56%	7.36%	-56.46%	225.6%
Alnylam Pharmaceuticals, Inc.	-0.55%	10.11%	28.49%	30.99%	109.19%
Vertex Pharmaceuticals Incorporated	-11.79%	-16.36%	-1.97%	78.33%	80.59%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Curis Inc	NA	NA	0.0	-6.81	-3.73	-0.46	NA	3.34
Regeneron Pharmaceuticals, Inc.	17.51	17.51	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.17	0.55	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Curis Inc	Buy	$26.1M	-90.13%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$77.8B	87.56%	17.51	33.61%
Biontech Se	Buy	$26.7B	225.6%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$30.8B	109.19%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$102.1B	80.59%	32.84	-4.51%

About Curis

curis is a publicly-traded biotechnology company (nasdaq: cris) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. curis’s pipeline of drug candidates includes cudc-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large b-cell lymphoma with alterations in the myc oncogene. curis is also engaged in a broad collaboration with aurigene in the areas of immuno-oncology and precision oncology. as part of this collaboration, curis has exclusive licenses to oral small molecule antagonists of the pd1 and vista pathways, including pdl1/vista antagonist ca-170, and oral small molecule antagonists of the pd1 and tim3 pathways, including pdl1/tim3 antagonist ca-327, as well as to molecules designed to inhibit the irak4 kinase, including ca-4948. ca-170 is currently undergoing testing in a phase 1 trial in patients with advanced solid tumors and lymphomas. ca-4948 is currentl

Organization	Curis
Employees	49
CEO	Mr. James E. Dentzer
Industry	Health Technology

Management People of Curis

Name	Title
Mr. James E. Dentzer	President, CEO, Secretary, Treasurer & Director
Ms. Diantha Duvall CPA, M.B.A.	CFO and Principal Financial & Accounting Officer
Dr. Jonathan B. Zung Ph.D.	Chief Development Officer
Mr. Mark W. Noel	Vice President of Technology Management & Intellectual Property
Dr. Robert E. Martell M.D., Ph.D.	Chief Scientific Officer
Ms. Elif McDonald	VP of Investor Relations & Corporate Communications
Dr. Reinhard Wilhelm von Roemeling M.D.	Senior Vice President of Clinical Development

Important FAQs about investing in Curis from India :

What is Curis share price today?

Curis share price today stands at $3.08, Open: $3.05 ; Previous Close: $3.07 ; High: $3.26 ; Low: $3.05 ; 52 Week High: $17.49 ; 52 Week Low: $3.05. The stock opens at $3.05, after a previous close of $3.07. The stock reached a daily high of $3.26 and a low of $3.05, with a 52-week high of $17.49 and a 52-week low of $3.05.

Can Indians buy Curis shares?

Yes, Indians can invest in the Curis (CRIS) from India.

With INDmoney, you can buy Curis at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Curis at zero transaction cost.

How can I buy Curis shares from India?

It is very easy to buy Curis from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Curis be purchased?

Yes, you can buy fractional shares of Curis with INDmoney app.

What are the documents required to start investing in Curis stocks?

To start investing in Curis, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.